SIU 2017: Long-Term Outcomes Following Laparoscopic Radiofrequency Ablation for T1a Renal Cell Carcinoma

Lisbon, Portugal (UroToday.com) Few studies have reported long-term outcomes of renal cell carcinoma (RCC) treated by radiofrequency ablation (RFA). The authors have reviewed their experience with cTla renal masses treated with laparoscopic RFA.

A total of 62 patients with cT1a renal masses treated between January 2005 and October 2014 were identified from a retrospective cohort. Patients with biopsy confirmed Tla RCC and a follow up period > 48 months were included in this analysis. Local recurrence, metastasis, survival rate and change in glomerular filtration rate (GFR) were analyzed.

The mean (range) follow-up for the laparoscopic RFA was 54.2 (26-97) months. The respective mean tumor size was 2.14 (+ 0.66) cm. The GFR was not significantly different at early follow up, but there was significant difference at the last follow up. There were no local recurrences, metastasis and disease-specific deaths during the entire follow-up period. The 5-year overall survival was 98%, cancer-specific survival was 100%, and recurrence-free survival was 100%.

This data showed that laparoscopic RFA for cTla renal masses has similar oncological and functional outcomes when compared to surgical treatment, but also to active surveillance. Longer follow-up time is required to truly understand the outcomes of this modality and its effects on clinical outcomes.


Presented by: Ji Yong Lee
Affiliation: Chungnam National University, Daejeon, South Korea

Written by: Hanan Goldberg, MD, Urologic Oncology Fellow (SUO), University of Toronto, Princess Margaret Cancer Centre.Twitter: @GoldbergHanan at the 37th Congress of Société Internationale d’Urologie - October 19-22, 2017- Lisbon, Portugal




email news signup